利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

30 条记录 (耗时 0.036 秒)

    Diagnosis and treatment of non-ulcer dyspepsia based on hypothalamic-pituitary-adrenal axis abnormallity
    25.
    发明申请
    Diagnosis and treatment of non-ulcer dyspepsia based on hypothalamic-pituitary-adrenal axis abnormallity 审中-公开
    基于下丘脑 - 垂体 - 肾上腺轴异常的非溃疡性消化不良的诊断和治疗

    公开(公告)号：US20030170731A1

    公开(公告)日：2003-09-11

    申请号：US10343433

    申请日：2003-03-17

    发明人： Timothy Garard Dinan ,  Paul William Napoleon Keeling

    IPC分类号： G01N033/53 ,  A61K031/53 ,  A61K031/519

    CPC分类号： G01N33/74 ,  G01N2333/5751

    摘要： An in vitromethod and a kit for the diagnosis of non-ulcer dyspepsia (NUD) in a subject suspected of having NUD, comprises identifying in the subject a dysfunction of corticotropin releasing hormone (CRH) receptors characterised by the subject's response to CRH-induced adrenocorticotropic hormone (ACTH) production by estimating the level of ACTH in a sample of blood or a blood fraction obtained from said subject relative to a control. The method can be used to diagnose NUD in patients who are infected with Helicobacter pylori and those who are free of such infection.

    摘要翻译： 一种用于诊断疑似患有NUD的受试者中的非溃疡性消化不良（NUD）的试剂盒，包括在受试者身上识别促肾上腺皮质激素（CRH）受体的功能障碍，其特征在于受试者对CRH诱导的促肾上腺皮质激素 激素（ACTH）产生，通过估计相对于对照从所述受试者获得的血样或血液分数中的ACTH水平。 该方法可用于诊断感染幽门螺杆菌的患者和无感染的患者的NUD。

    Cyclic CRF agonists
    27.
    发明授权
    Cyclic CRF agonists 有权
    循环CRF激动剂

    公开(公告)号：US06326463B1

    公开(公告)日：2001-12-04

    申请号：US09424889

    申请日：1999-11-29

    申请人： Jean E. F. Rivier

    发明人： Jean E. F. Rivier

    IPC分类号： A61K3828

    CPC分类号： C07K14/57509 ,  A61K38/00 ,  G01N33/566 ,  G01N33/68 ,  G01N33/74 ,  G01N2333/5751 ,  Y10S930/26

    摘要： Novel cyclic CRF agonist peptides have the amino acid sequence: (cyclo 30-33)Ac-Ser-Leu-Asp-Leu-Thr-D-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Nle-Ala-Arg-Ala-Glu-Gln-Leu-Ala-Gln-Glu-Ala-R32-R33-Asn-Arg-Lys-Leu-Nle-Glu-Ile-Ile-NH2 wherein R32 is His, D-His or an equivalent &agr;-amino acid; R33 is Lys or Orn. The N-terminus may be extended by Tyr, D-Tyr or Ile. Lys may be substituted for Arg23, and its side chain connected by a lactam bridge to Glu20 to form a bicyclic peptide. Certain disclosed CRF agonists include: (cyclo 30-33)[Ac-Ser7, D-Phe12, Nle21,38, Glu30, Lys33]r/hCRF(7-41); (cyclo 30-33)[Ac-Ser7, D-Phe12, Nle21,38, Glu30, D-His32, Lys33]r/hCRF(7-41); (bicyclo 20-23, 30-33)[Ac-Ser7, D-Phe12, Nle21,38, Lys23,33, Glu30, D-His32]-r/hCRF(7-41); (cyclo 30-33)[Ac-Ser7, D-Phe12, Nle18,21, Glu30, D-Ala32, Lys33]&agr;-helicale CRF(7-41); and (cyclo 30-33)[Ac-Ser7, D-Phe12, Nle21,38, CML27,40, Glu30, Lys33]r/hCRF(7-41). Labelled agonist such as (cyclo 30-33)[Ac-I125Tyr6, D-Phe12, Nle21,38, Glu30, Lys33]r/hCRF(6-41) and (cyclo 30-33)[Ac-I125D-Tyr6, D-Phe12, Nle21,38, Glu30, D-His32, Lys33]r/hCRF(6-41) are useful in screening for more potent CRF agonists.

    摘要翻译： 新型循环CRF激动剂肽具有氨基酸序列：（环30-33）Ac-Ser-Leu-Asp-Leu-Thr-D-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Nle -Ala-Arg-Ala-Glu-Gln-Leu-Ala-Gln-Glu-Ala-R32-R33-Asn-Arg-Lys-Leu-Nle-Glu-Ile-Ile-NH2，其中R32是His，D-His 或等效的α-氨基酸; R33是Lys或Orn。 N末端可以被Tyr，D-Tyr或Ile延伸。 Lys可以代替Arg23，其侧链通过内酰胺桥连接至Glu20以形成双环肽。 某些公开的CRF激动剂包括：（环30-33）[Ac-Ser7，D-Phe12，Nle21,38，Glu30，Lys33] r / hCRF（7-41）; （环30-33）[Ac-Ser7，D-Phe12，Nle21,38，Glu30，D-His32，Lys33] r / hCRF（7-41）; （双环20-23,30-33）[Ac-Ser7，D-Phe12，Nle21,38，Lys23,33，Glu30，D-His32] -r / hCRF（7-41）; （环30-33）[Ac-Ser7，D-Phe12，Nle18,21，Glu30，D-Ala32，Lys33]α-螺旋CRF（7-41）; 和（环30-33）[Ac-Ser7，D-Phe12，Nle21,38，CML27,40，Glu30，Lys33] r / hCRF（7-41）。 标记的激动剂如（环30-33）[Ac-I125Tyr6，D-Phe12，Nle21,38，Glu30，Lys33] r / hCRF（6-41）和（环30-33）[Ac-I125D-Tyr6，D -Phe12，Nle21,38，Glu30，D-His32，Lys33] r / hCRF（6-41）可用于筛选更有效的CRF激动剂。

    Cyclic CRF antagonist peptides
    28.
    发明授权
    Cyclic CRF antagonist peptides 有权
    循环CRF拮抗肽

    公开(公告)号：US06323312B1

    公开(公告)日：2001-11-27

    申请号：US09424127

    申请日：1999-11-17

    申请人： Jean E. F. Rivier

    发明人： Jean E. F. Rivier

    IPC分类号： A61K3812

    CPC分类号： G01N33/74 ,  A61K38/00 ,  C07K14/57509 ,  G01N33/566 ,  G01N2333/5751

    摘要： Novel cyclic CRF antagonist peptides are created by shortening the N-terminus of a CRF family peptide by 8 residues and adding an acyl group. CML is present in what would be the 27-position of the native CRF sequence, and a cyclizing bond is created between the side chains of the residues in positions 30 and 33. The side chain of Lys, preferably, in position 33 is linked to the side chain of Glu in position 30 by a lactam bridce. Disclosed CRF antagonists include: (cyclo 30-33)[Ac-Asp9, D-Phe12, Nle21,38, CML27,40, Glu30, Lys33]r/hCRF(9-4); (cyclo 30-33)[Ac-Asp9, D-Phe12, CML18,27, Nle21,38, Glu30, Lys33]r-hCRF(9-41); (cyclo 30-33)[Ac-Asp9, D-Phe12, Nle21,38, CML27,37, Glu30, Lys33]r/hCRF(9-41); (cyclo 30-33)[Ac-Asp9, D-Phe12, CML14,27, Nle21,38, Glu30, Lys33]r/hCRF(9-41); (cyclo 30-33)[Ac-Asp9, D-Phe12, Nle21,38, CML27, Glu30, Lys33]r/hCRF(9-41); and (cyclo 30-33)[Ac-Asp9, D-Phe12, Nle21,38, CML27,40, Glu30, Aib32, Lys33]r/hCRF(9-41).

    摘要翻译： 通过将CRF家族肽的N末端缩短8个残基并加入酰基来产生新的循环CRF拮抗剂肽。 CML存在于天然CRF序列的27位上，并且在位置30和33的残基的侧链之间产生环化键。Lys的侧链优选位于33位与 位置30处的Glu的侧链通过内酰胺桥接。 公开的CRF拮抗剂包括：（环30-33）[Ac-Asp9，D-Phe12，Nle21,38，CML27,40，Glu30，Lys33] r / hCRF（9-4）; （环30-33）[Ac-Asp9，D-Phe12，CML18,27，Nle21,38，Glu30，Lys33] r-hCRF（9-41）; （环30-33）[Ac-Asp9，D-Phe12，Nle21,38，CML27,37，Glu30，Lys33] r / hCRF（9-41）; （环30-33）[Ac-Asp9，D-Phe12，CML14,27，Nle21,38，Glu30，Lys33] r / hCRF（9-41）; （环30-33）[Ac-Asp9，D-Phe12，Nle21,38，CML27，Glu30，Lys33] r / hCRF（9-41）; 和（环30-33）[Ac-Asp9，D-Phe12，Nle21,38，CML27,40，Glu30，Aib32，Lys33] r / hCRF（9-41）。

    9H-pyrimido [4,5-b] indole derivatives: CRF1 specific ligands
    29.
    发明授权
    9H-pyrimido [4,5-b] indole derivatives: CRF1 specific ligands 失效
    9H-嘧啶并[4,5-b]吲哚衍生物：CRF1特异性配体

    公开(公告)号：US06284766B1

    公开(公告)日：2001-09-04

    申请号：US09561569

    申请日：2000-04-28

    申请人： Raymond F. Horvath

    发明人： Raymond F. Horvath

    IPC分类号： A01N4354

    CPC分类号： C07D487/04 ,  G01N2333/5751 ,  G01N2333/726

    摘要： Disclosed are compounds of the formula: wherein Ar, R1, R2, R3, R4 and R5 are defined herein, which compounds are selective antagonists at CRF1 receptors and are therefore useful in the diagnosis and treatment of stress related disorders such as post traumatic stress disorder (PTSD) as well as depression, headache, anxiety, cardiovascular disorders, and eating disorders. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also disclosed.

    摘要翻译： 公开了下式的化合物：其中Ar，R 1，R 2，R 3，R 4和R 5在本文中定义，这些化合物是CRF1受体的选择性拮抗剂，因此可用于诊断和治疗应激相关疾病如创伤后应激障碍 （PTSD）以及抑郁，头痛，焦虑，心血管疾病和饮食失调。 还公开了治疗这种病症以及包装的药物组合物的方法。

    Cyclic CRF antagonist peptides
    30.
    发明授权
    Cyclic CRF antagonist peptides 失效
    循环CRF拮抗肽

    公开(公告)号：US5777073A

    公开(公告)日：1998-07-07

    申请号：US865773

    申请日：1997-05-30

    申请人： Jean E. F. Rivier

    发明人： Jean E. F. Rivier

    IPC分类号： A61K38/00 ,  A61P1/00 ,  A61P25/00 ,  C07K14/575 ,  G01N33/15 ,  G01N33/50 ,  G01N33/566 ,  G01N33/74 ,  A61K38/28 ,  A61K38/35 ,  C07K5/00 ,  C07K7/00

    CPC分类号： G01N33/566 ,  C07K14/57509 ,  G01N33/74 ,  A61K38/00 ,  G01N2333/5751 ,  Y10S930/26 ,  Y10S930/27

    摘要： Novel cyclic CRF antagonist peptides are created by shortening the N-terminus of a CRF family peptide by 8-11 residues and adding an acyl group. CML is preferably present in what would be the 27-position of the native CRF sequence, and D-Tyr may be incorporated at the N-terminus to facilitate labelling. The cyclizing bond is preferably created between the side chains of the residues in positions 30 and 33; but it may alternatively be created between the residues in either of positions 28 and 29 with those in positions 31 and 32 or with those in positions 32 and 33, respectively. The side chain of Lys in position 33 is preferably linked to the side chain of Glu in position 30 by a lactam bridge to form the cyclic peptide. Disclosed CRF antagonists include: (cyclo 30-33) �Ac-Asp.sup.9, D-Phe.sup.12, Nle.sup.21,38, CML.sup.27,40, Glu.sup.30, Lys.sup.33 !r/hCRF(9-41), (cyclo 30-33) �Ac-Asp.sup.9, D-Phe.sup.12, Nle.sup.21,38, CML.sup.27,37, Glu.sup.30, Lys.sup.33 !r/hCRF(9-41), (cyclo 30-33) �Ac-Asp.sup.9, D-Phe.sup.12, CML.sup.14,27, Nle.sup.21,38, Glu.sup.30, Lys.sup.33 !r/hCRF(9-41), (cyclo 30-33) �Ac-Asp.sup.9, D-Phe.sup.12, Nle.sup.21,38, CML.sup.27, Glu.sup.30, Lys.sup.33 !r/hCRF(9-41), (cyclo 30-33) �Ac-Asp.sup.9, D-Phe.sup.12, CML.sup.18,27, Nle.sup.21,38, Glu.sup.30, D-His.sup.32, Lys.sup.33 !r/hCRF(9-41) and (cyclo 30-33) �Ac-Asp.sup.9, D-Phe.sup.12, CML.sup.18,27, Nle.sup.21,38, Glu.sup.30, Lys.sup.33 !r/hCRF(9-41).

    摘要翻译： 通过将CRF家族肽的N末端缩短8-11个残基并加入酰基来产生新的循环CRF拮抗剂肽。 CML优选存在于天然CRF序列的27位上，并且D-Tyr可以并入N末端以促进标记。 优选在位置30和33之间的残基的侧链之间产生环化键; 但也可以分别在位置28和29之间的残基与位置31和32中的残基之间或位于第32和33位的残基之间产生。 位置33处的Lys侧链优选通过内酰胺桥连接于位置30的Glu侧链以形成环肽。 公开的CRF拮抗剂包括：（环30-33）[Ac-Asp9，D-Phe12，Nle21,38，CML27,40，Glu30，Lys33] r / hCRF（9-41），（环30-33）[Ac- Asp9，D-Phe12，Nle21,38，CML27,37，Glu30，Lys33] r / hCRF（9-41），（环30-33）[Ac-Asp9，D-Phe12，CML14,27，Nle21,38， Glu30，Lys33] r / hCRF（9-41），（环30-33）[Ac-Asp9，D-Phe12，Nle21,38，CML27，Glu30，Lys33] r / hCRF（9-41），（环30 -33）[Ac-Asp9，D-Phe12，CML18,27，Nle21,38，Glu30，D-His32，Lys33] r / hCRF（9-41）和（环30-33）[Ac-Asp9， Phe12，CML18,27，Nle21,38，Glu30，Lys33] r / hCRF（9-41）。